百家乐怎么玩-澳门百家乐官网娱乐城网址_网上百家乐是不是真的_全讯网888 (中国)·官方网站

First dual stem cell therapy brings new hope for cardiac repair

Donna Wong

 

190910-1_research_0.jpg
Dr Ban Ki-won (middle) and his research team at CityU.

 

A research team featuring an expert from City University of Hong Kong (CityU) has developed a novel dual approach for the first time for concurrently rejuvenating both the cardiac muscle and vasculature of the heart by utilising two types of stem cells. The results give hope for a new treatment for repairing myocardial infarction (MI) heart. 

  190910-2_research_1.jpg
These are the specimens of rats’ hearts used in the research.

 

Dr Ban Ki-won, Assistant Professor of the Department of Biomedical Sciences and his research team, including researchers from Konkuk University, The Catholic University of Korea, Pohang University of Science and Technology and T&R Biofab in South Korea, have conducted the first study of two distinct stem cell effects for cardiac repair. The two major types of stem cells employed are human bone marrow derived mesenchymal stem cells (hMSCs) and cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CMs). The research findings have been published in Nature Communications in a paper titled “Dual stem cell therapy synergistically improves cardiac function and vascular regeneration following myocardial infarction”. 

“Both cardiac muscles and vasculatures are severely damaged following MI, and so the therapeutic strategies should focus on comprehensive repair of both at the same time. But the current strategies only focus on either one,” Dr Ban said. 

Dr Ban said that, with limited therapeutic options for severe MI and advanced heart failure, a heart transplant was the last resort. However, such an operation is very risky, costly and subject to limited supply of suitable donors. Therefore, stem cell-based therapy has emerged as a promising therapeutic option.

190910-3_research_4.jpg
Representative immunostaining images showing hiPSC-CM-GFP (green) and MYH6/7 gene (red) when hiPSC-CMs were injected in MI hearts.

 

In the study, the hiPSC-CMs were injected directly into the border zone of the rat's heart, while the hMSCs-loaded patch was implanted on top of the infarct area, like a bandage. The results showed that this dual approach led to a significant improvement of cardiac function and an enhancement of vessel formation on a MI heart. 

“We believe this novel dual approach can potentially provide translational and clinical benefit to the field of cardiac regeneration. Based on the same principle, the protocol may also be utilised for repairing other organs including the brain, liver and pancreas in which multiple types of stem cells co-exist,” Dr Ban added. 

The research team is working on follow-up studies in larger animal models such as pigs. The patent application for this research result has been submitted.

The first co-authors of the paper are Dr Park Soon-jung from Konkuk University School of Medicine, Dr Kim Ri-youn and PhD student Lee Sung-hun from CityU and PhD student Park Bong-woo from The Catholic University of Korea.

 

 

YOU MAY BE INTERESTED

Contact Information

Communications and Institutional Research Office

Back to top
百家乐官网五湖四海娱乐网| 百家乐官网自动投注| 钱柜娱乐城现金网| 百家乐官网双龙出海注码法| 大发888娱| 太阳城宾馆| 盐城百家乐官网的玩法技巧和规则| 做生意摆放风水| 北流市| 综合百家乐博彩论坛| 澳门百家乐官网娱乐场开户注册| 太阳城百家乐分析解码| 大发888在线娱乐城合作伙伴| 百家乐官网娱乐城优惠| 大发888东方鸿运| 百家乐电话投注怎么玩| 嵩明县| 大发888客户端de 软件| 百家乐如何取胜| 百家乐官网网站哪个好| 虚拟百家乐官网游戏下载| 德州扑克大赛| 鑫鑫百家乐官网的玩法技巧和规则 | 金莎国际娱乐| 索雷尔百家乐的玩法技巧和规则 | 娱乐场| 百家乐分| 百家乐扑克多少张| 免费百家乐规则| 新澳博百家乐官网娱乐城| k7线上娱乐| 棋牌小游戏下载| 大发888黄金版下载| 巴黎百家乐地址| 坐乾向巽24山向择吉| 金龍百家乐官网的玩法技巧和规则 | 优博信誉| 孙吴县| 长城百家乐官网游戏| 大发888开户注册网站| 博雅德州扑克下载|